NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical...
Dr. Gül Dölen, MD, PhD, to share groundbreaking research on how psychedelic compounds can reopen “critical periods” of brain plasticity....
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for...
Deep TMS Takes Center Stage with Compelling ResearchBURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ...
WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer...
Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in...
SARASOTA, Fla., June 10, 2025 /PRNewswire/ -- World Precision Instruments (WPI), the global leader in transepithelial electrical resistance (TEER) technology, in...
Join Us in San Francisco, October 27-28! REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- The Tianqiao and Chrissy Chen...
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized dosing and therapeutic support for...
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025...
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with...
Top three teams recognized for ideas to create sustainable electric mobility, tumor diagnostics accuracy and remote neurological monitoring BENGALURU, India,...
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or...
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of...
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June...
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to...
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirementNEWTOWN, Pa., June 04, 2025...
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...
Partnership to provide demand generation, thought leadership, and media services BALTIMORE, June 3, 2025 /PRNewswire/ -- Sage Growth Partners (SGP), a healthcare growth...